Pulmonary Hypertension Associated With Interstitial Lung Disease
Cardiovascular·MeSH: Hypertension, Pulmonary
Prevalence
47000.0 / 100K
Incidence
3000.0 / 100K/yr
3 drugs in development·3 companies·1 clinical trial
Drug Pipeline by Phase
Approved(2)
Phase 2(1)
| Drug | Company |
|---|---|
| mosliciguat | Roivant Sciences Ltd. (ROIV) |
Compare drugs
Frequently asked questions
How many drugs are in development for Pulmonary Hypertension Associated With Interstitial Lung Disease?
BioSniper tracks 3 drugs in development for Pulmonary Hypertension Associated With Interstitial Lung Disease across 3 companies.
How many clinical trials target Pulmonary Hypertension Associated With Interstitial Lung Disease?
There are 1 clinical trial targeting Pulmonary Hypertension Associated With Interstitial Lung Disease tracked by BioSniper.
What is the prevalence of Pulmonary Hypertension Associated With Interstitial Lung Disease?
The estimated prevalence of Pulmonary Hypertension Associated With Interstitial Lung Disease is approximately 47000.0 per 100,000 population.
Deep-dive into Pulmonary Hypertension Associated With Interstitial Lung Disease
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis